Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced breast cancer diagnosed by guided core biopsy~* T \> 2 cm (any N), or any T and node positive (needle biopsy is required)~* Non-metastatic disease assessed by computed tomography and bone scintigraphy~* Histological grade 2 and Ki67 \> 15% or~* Histological grade 3 or~* Any triple negative (TN) or~* Inflammatory breast cancer (IBC)~* Normal left ventricular ejection fraction (LVEF)~* HER2-negative disease~Exclusion Criteria:~* Another malignancy within the last 5 years (except curatively treated skin carcinoma, in situ cervix carcinoma, in situ ductal carcinoma of the breast, or in situ lobular carcinoma of the breast)~* Clinically significant comorbidities as cardiovascular diseases, chronic obstructive pulmonary disease (COPD), renal or liver failure, psychiatric disorders~* LVEF value below institutional limits of normal~* Predominant lobular carcinoma histology~* Grade 1 tumors~* Detected or suspicious distant metastasis~* Neutrophils less than 1,500/µL, platelets less than 100,000/µL, hemoglobin less than 10 g/dL, AST more than 2.5x upper limit of normal (ULN), total bilirubin more than ULN, alkaline phosphatase more than 1.5x ULN~* Male sex~* HER2-positive breast cancer

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel/doxorubicin/cyclophosphamide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).